PhaseBio Pharmaceuticals Inc

NASDAQ:PHAS   3:59:54 PM EDT
3.71
+0.14 (+3.92%)
Earnings Announcements

PhaseBio Reports Q3 2020 Financial Results

Published: 11/12/2020 21:27 GMT
PhaseBio Pharmaceuticals Inc (PHAS) - Phasebio Reports Recent Business Highlights and Third-quarter 2020 Financial Results.
Phasebio Pharmaceuticals - Cash and Cash Equivalents at September 30, 2020 Were $39.4 Million, Compared to $74.0 Million at December 31, 2019.
Phasebio Pharmaceuticals - Qtrly Loss per Share $0.86.
Revenue is expected to be $0.18 Million
Adjusted EPS is expected to be -$0.70

Next Quarter Revenue Guidance is expected to be $0.15 Million
Next Quarter EPS Guidance is expected to be -$0.75

More details on our Analysts Page.